UK has bought 30m doses of product that could transform world’s immunisation programmes
A fifth vaccine, made by the US company Johnson & Johnson, has shown efficacy against the coronavirus and could transform prospects for protecting both the UK and the rest of the world, because it needs only a single dose.
The vaccine, made by the US giant’s subsidiary Janssen, based in the Netherlands, was trialled in the UK – and the British government has bought 30m doses. The EU has ordered 400m doses.
UK has bought 30m doses of product that could transform world’s immunisation programmes
A fifth vaccine, made by the US company Johnson & Johnson, has shown efficacy against the coronavirus and could transform prospects for protecting both the UK and the rest of the world, because it needs only a single dose.
The vaccine, made by the US giant’s subsidiary Janssen, based in the Netherlands, was trialled in the UK – and the British government has bought 30m doses. The EU has ordered 400m doses.
UK has bought 30m doses of product that could transform world’s immunisation programmes
A fifth vaccine, made by the US company Johnson & Johnson, has shown efficacy against the coronavirus and could transform prospects for protecting both the UK and the rest of the world, because it needs only a single dose.
The vaccine, made by the US giant’s subsidiary Janssen, based in the Netherlands, was trialled in the UK – and the British government has bought 30m doses. The EU has ordered 400m doses.
